Table 1

Characteristics of phase 2 trial sites
Site Participants (RTS,S) Active vaccine Median age (IQR) Parasite prevalencea Schedule Peak anti-CSP titre (95% range)
Gambia [[12]] 250 (136) RTS,S/AS02A 24 (19 to 34) years 70% 0,1,5,14 months 25 (13 to 43) μg/mL
Kisumu, Kenya [[13]] 250 (159) RTS,S/AS02A and RTS,S/AS01B 25 (21 to 29) years 60% 0,1,2 months 34 (2 to 210) EU/mL
Manhica, Mozambique (cohort 1) [[7],[14]] 1,589 (768) RTS,S/AS02A 35 (24 to 48) months 40% 0,1,2 months 191 (9 to 916) EU/mL
Ilha Josina, Mozambique (cohort 2) [[7],[14]] 411 (196) RTS,S/AS02A 36 (24 to 45) months 45% 0,1,2 months 266 (16 to 1,390) EU/mL
Kilifi, Kenya [[6],[15]] 447 (209) RTS,S/AS01E 11 (8 to 14) months 35% 0,1,2 months 580 (104 to 1,922) EU/mL
Korogwe, Tanzania [[6]] 447 (224) RTS,S/AS01E 12 (9 to 15) months 15% 0,1,2 months 493 (138 to 1,768) EU/mL
Kintampo, Ghana [[10]] 180 (180) RTS,S/AS02D and RTS,S/AS01E 11 (8 to 14) months 80% 0,1,2 and 0,1,7 months 465 (73 to 2,632)b EU/mL
Kumasi, Ghana [[10]] 270 (270) RTS,S/AS02D and RTS,S/AS01E 11 (7 to 13) months 35% 0,1,2 and 0,1,7 months 460 (84 to 1,785)b EU/mL
Lambaréné, Gabon [[9]] 180 (180) RTS,S/AS02D and RTS,S/AS01E 38 (31 to 48) months 5% 0,1,2 months 198 (32 to 888) EU/mL
Bagamoyo, Tanzania [[8]] 209 (136) RTS,S/AS01E 1.8 (1.7 to 1.9) months 30% 0,1,2 and 0,1,7 monthsc 167 (14 to 934)b EU/mL
Lambaréné, Gabon [[8]] 215 (139) RTS,S/AS01E 1.5 (1.4 to 1.7) months 5% 0,1,2 and 0,1,7 monthsc 337 (97 to 1,836)bEU/mL
Kintampo, Ghana [[8]] 81 (52) RTS,S/AS01E 1.6 (1.5 to 1.8) months 80% 0,1,2 and 0,1,7 monthsc 70 (11 to 455)b EU/mL
Mozambique infants [[16]] 214 (98) RTS,S/AS02D 1.8 (1.8 to 2.1) months 45% 0,1,2 months 211 (6 to 1,008) EU/mL
Bagamoyo, Tanzania [[11]] 340 (157) RTS,S/AS02D 1.9 (1.8 to 2) months 30% 0,1,2 monthsc 87 (1 to 572)b EU/mL

For participants receiving at least one dose of RTS,S the peak anti-CSP antibody titre following vaccination is presented as the median and 95% range within the cohort at each trial site. aAge-corrected parasite prevalence in 2- to 10-year olds taken from Malaria Atlas Project [[17]]; bindicates peak anti-CSP antibody titre in the cohort vaccinated through a 0, 1, 2 month schedule; cindicates co-administration with the EPI vaccines (diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenza type b). CSP, circumsporozoite protein; EPI, expanded programme on immunization; EU, ELISA units; IQR, interquartile range.

White et al.

White et al. BMC Medicine 2014 12:117   doi:10.1186/s12916-014-0117-2

Open Data